AltaSolvix is developing pharmaceutical-grade stabilized cannabinoid acid therapeutics, beginning with a lead program targeting rare pediatric epilepsy — built on licensed university chemistry and a rigorous, data-driven development approach.
Our stabilization platform is designed to be adaptable. The same foundational chemistry that enables our lead program opens structured pathways into a range of conditions where the underlying biology has historically been inaccessible due to molecular instability.
All indications below reflect published pharmacological literature and scientific rationale — not active clinical programs. Lead development focus is rare pediatric epilepsy.
Treatment-resistant seizure disorders including Dravet syndrome represent a validated orphan indication with established FDA precedent, payer acceptance, and significant unmet need despite existing approved therapies.
A related severe developmental epileptic encephalopathy with overlapping pharmacological rationale and existing regulatory framework, representing a natural expansion of the lead program.
CINV affects a significant proportion of oncology patients and remains incompletely managed by current antiemetics. Preclinical literature supports cannabinoid acid involvement in relevant receptor pathways.
An $8B+ global market where cannabinoid pharmacology has demonstrated preclinical and early clinical signal. Platform chemistry may offer routes not achievable with current cannabinoid forms.
Receptor profiles implicated in inflammatory signaling (PPARγ, TRPV1) align with biological mechanisms relevant to multiple inflammatory disease contexts.
Selected movement disorders represent a potentially faster development pathway with favorable regulatory precedent in the cannabinoid therapeutic class.
CBDA — the acidic precursor to FDA-approved CBD — demonstrates differentiated pharmacological properties in preclinical research. One structural vulnerability has prevented its development as a regulated pharmaceutical. We are addressing that at the molecular level.
Degrades Within Weeks
Without stabilization, CBDA degrades rapidly under standard pharmaceutical handling and storage conditions — converting to a distinct compound and losing its properties.
No Pharma-Grade Source Exists
Botanical-derived CBDA averages 60–75% purity with inconsistent batch-to-batch quality. No pharmaceutical-grade, reliably pure CBDA supply currently exists.
Patients Without Options
Children with treatment-resistant epilepsies such as Dravet syndrome often exhaust existing therapies. Differentiated candidates with a clear FDA pathway represent an open clinical opportunity.
AltaSolvix's platform applies a proprietary stabilization approach — licensed from the University of Colorado Boulder — that dramatically extends the shelf-life and pharmaceutical-grade handling of CBDA, enabling regulated drug development that was previously not achievable with this compound class.
Exclusive evaluation license covering proprietary CBDA stabilization chemistry, including composition, synthesis method, and formulation claims. Prosecution is ongoing.
Published preclinical literature indicates CBDA demonstrates differentiated receptor modulation profiles compared to CBD — potentially relevant in treatment-resistant epilepsy populations.
Stabilization chemistry is adaptable across structurally related cannabinoid acids. Shared analytical methods and manufacturing workflows provide a structured development foundation.
Epidiolex established a regulatory pathway for cannabinoids. Lead indication benefits from precedent and eligibility for orphan drug designation and rare pediatric disease incentives.
AltaSolvix operates a lean, data-driven development model. We work with specialized contract partners for laboratory execution while maintaining full scientific, regulatory, and intellectual property control in-house. Every development decision is tied to predefined criteria.
Milestone-Gated Execution
Each activity answers one decisive scientific or regulatory question with predefined success criteria — eliminating ambiguity and protecting capital.
Lean, Outsourced, Colorado-Based
GMP synthesis, analytical validation, and stability testing via specialized partners. No fixed manufacturing overhead.
FDA-Aligned from Day One
Pre-IND engagement is a core deliverable. CMC documentation and data integrity practices are built to IND standards throughout.
We partner with Trualis, powered by the Twine protocol — a distributed cryptographic data integrity layer. Trualis connects every stage of development into a single, immutable, auditable record.
Every data package is time-stamped and sealed at generation. Post-hoc alteration is not possible or deniable.
Connects CRO transfers, experimental outputs, and document versioning into one auditable timeline.
Data integrity practices aligned to FDA expectations from day one — without a heavy early-stage validated LIMS.
Shared datasets carry verifiable provenance — reducing diligence friction for licensing and co-development.
AltaSolvix is embedded in a university-linked biotech ecosystem with access to scientific, regulatory, and entrepreneurial resources.
Over a decade of experience in regulated industries spanning pharmaceutical supply chains, microfinance, and agriculture. PMP-certified with an MSc in Management. Track record managing large portfolios and scaling supplier value chains across regulated environments.
Synthetic chemist at the University of Colorado Boulder and inventor of the proprietary stabilization technology. Prior R&D leadership at Shell, Sievers, and Agilent. Ongoing collaboration provides access to IP, facilities, and analytical instrumentation.
Senior Director of Digital & Precision Medicine. Expertise in FDA/EMA strategy, DMF and IND submissions, and rare disease frameworks. Led regulatory-grade analytics and data integrity frameworks for international pharma consortia.
Whether you are a pharmaceutical partner, investor, researcher, or potential advisor — we welcome the conversation.